The study led by researchers at King's College London (UK), Karolinska Institutet (Sweden) and Mount Sinai School of Medicine in New York (US) is the first to compare all available In vitro fertilisation (IVF) treatments and the risk of neurodevelopmental disorders in children.
By using anonymous data from the Swedish national registers, researchers analysed more than 2.5 million birth records from 1982 and 2007 and followed-up whether children had a clinical diagnosis of autism or intellectual disability (defined as having an IQ below 70) up until 2009.
"IVF treatments are vastly different in terms of their complexity. When we looked at IVF treatments combined, we found there was no overall increased risk for autism, but a small increased risk of intellectual disability," said Sven Sandin, co-author of the study from King's College London's Institute of Psychiatry.
"When we separated the different IVF treatments, we found that 'traditional' IVF is safe, but that IVF involving ICSI, which is specifically recommended for paternal infertility is associated with an increased risk of both intellectual disability and autism in children," Sandin said.
Compared to spontaneous conception, children born from any IVF treatment were not at an increased risk of autism, but were at a small increased risk of intellectual disability (18 per cent increase - from 39.8 to 46.3 per 100,000 person years). However, the risk increase disappeared when multiple births were taken into account.
Children born after IVF treatments with ICSI (with either fresh or frozen embryos) were at a higher risk of intellectual disability (51 per cent increase - 62 to 93 per 100,000). This association was even higher when a preterm birth also occurred (73 per cent increase - 96 to 167 per 100,000).
Children born after IVF with ICSI using surgically extracted sperm and fresh embryos were at an increased risk of autism but the association disappeared when multiple births were taken into account, researchers found.
The study was published in the Journal of the American Medical Association.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
